Precision Diagnosis and Care for Families With Pulmonary Fibrosis in Ireland (PRECISE-PF)

November 20, 2024 updated by: Royal College of Surgeons, Ireland

Precision Diagnosis and Care for Families With Pulmonary Fibrosis in Ireland [PRECISE-PF]

This study aims to improve the understanding of how genes and the environment can influence and cause pulmonary fibrosis. By identifying the presence of genes and other factors that can put people at risk of developing pulmonary fibrosis, the influence these factors have on the progression of the disease can be studied.

Interstitial lung disease (ILD) is the medical term given to a group of lung diseases affecting the same part of the lung, the interstitium, each with similar symptoms. In some of these diseases, inflammation leads to lung scarring, known as fibrosis. Idiopathic Pulmonary Fibrosis (IPF) is one of these diseases; it has a particular pattern on computed tomography (CT) scans. IPF is 'idiopathic' as it is not yet fully understood why it happens. It has a poor prognosis. The average survival time is three to five years after diagnosis. While new antifibrotic drugs offer hope of slowing disease progression, lung transplant is the only cure, and it comes with its significant risks.

Although it is not fully understood what causes IPF, it is known that genetic factors significantly increase the risk of developing the disease. Up to a quarter (25%) of people with IPF with a family history appear to have a causative genetic variant. Familial-pulmonary-fibrosis (FPF), the term for people with at least one relative with IPF, may have worse disease when compared to those without a family history. However, this needs more research. Patients with specific genes, telomere-related gene variants, appear to have a greater risk of developing blood disorders from medications given to suppress the body's immune system after a lung transplant.

Progressive pulmonary fibrosis is pulmonary fibrosis where there is irreversible worsening of the disease, worsening of lung function, respiratory symptoms and even early death. It is of growing importance regardless of the cause, whether it be idiopathic, familial or secondary to a connective tissue disease. ILD is increasingly recognised as a complication of connective tissue diseases. It is the leading cause of death in people with systemic sclerosis. The new antifibrotic drugs slow the progression of CTD-ILD. People with progressive pulmonary fibrosis who have a greater than 10% drop over one year in a measure of their lung function, called the forced vital capacity, benefit most from antifibrotic therapy. Early identification of people with progressive disease would allow the commencement of treatment quicker. At-home spirometry may be a way of identifying those who are worsening early.

This study hypothesises that by improving knowledge of factors that affect disease behaviour and progression and assessing tools for the early identification of progressive disease, such as at-home spirometry and CT scan pattern determination by deep-learning analysis, we can provide 'precision' diagnosis and treatment. It is hoped that this improved understanding will help reduce the clinical risk for people with pulmonary fibrosis and their families.

This study aims to recruit 300 patients: 100 with IPF, 100 with FPF, and 100 with CTD ILD. Each participant will be followed for one year.

This observational study aims to help answer a number of questions:

  1. What genetic variants cause people to develop ILD, and which increase a person's risk of developing ILD are present in the study population?
  2. How does pulmonary fibrosis behave in people who have a family history of IPF compared to those who do not and in people with CTD-ILD?
  3. Are different types of pulmonary fibrosis more progressive than others i.e. Is pulmonary fibrosis in those with a family history of pulmonary fibrosis more progressive than in those who do not have a family history?
  4. Is the disease in those with a genetic variant known to cause ILD worse than in those who don't have a gene?
  5. Can at-home spirometry help identify people at risk of progressive disease early?
  6. Can deep-learning analysis (AI) be used to find CT scan patterns to predict when pulmonary fibrosis will worsen?

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Estimated)

300

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • Ireland
      • Dublin, Ireland, D09V2N0
        • Recruiting
        • Beaumont Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Participants who meet the study criteria will be recruited from the rheumatology and respiratory clinics in Beaumont Hospital, a tertiary hospital in Dublin, Ireland.

Description

Inclusion Criteria:

  • Able and willing to give written informed consent.

  • An MDT diagnosis of fibrotic ILD which fall into one of the following three catagories;

    1. Have a multidisciplinary team (MDT) diagnosis of a fibrotic interstitial lung disease, reporting one or more relatives with a fibrotic form of ILD
    2. Have a MDT diagnosis of IPF in accordance with consensus criteria, ATS, ERS, JRS, ALAT guidelines without a family history of pulmonary fibrosis.
    3. Meet the American College of Rheumatology/European League Against Rheumatism criteria for rheumatoid arthritis, scleroderma, Sjogren's syndrome, idiopathic inflammatory myopathy and systemic lupus erythematosus.

Exclusion Criteria:

  • Currently participating in an interventional clinic trial.
  • Change in clinical phenotype from initial radiological diagnosis to screening.
  • Acute or chronic hypersensitivity pneumonitis with consensus criteria (appropriate exposure history, radiological features ± avian and fungal precipitins).
  • Asbestosis (appropriate occupational history and radiological evidence of asbestos exposure)
  • Life expectancy for any disease, including ILD <12 months (investigator assessment)
  • Major extrapulmonary physiological restriction (e.g. chest wall abnormality, large pleural effusion)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Familial pulmonary fibrosis group
Patients meeting the study inclusion criteria with an multidisciplinary team (MDT) diagnosis of a fibrotic interstitial lung disease, reporting one or more relatives with a fibrotic form of ILD
Diagnostic test: Six minute walk test (6MWT)
Assessment of exercise capacity by the carrying out of a 6MWT at 0, 6 and 12 months.
Diagnostic test: Computer-tomography of the thorax (CT Thorax)
Radiological assessment via CT Thorax, preferably high-resolution CT thorax at baseline on entering the study and at one year. CT images will be collected on study end. CT images in all subjects will be evaluated by three readers blinded to any other interpretation and conforming to ATS-guidelines. Coded data from CT scans will be shared with our collaborator Professor Simon Walsh at Imperial College, London who will use computational methods to identify novel radiologic phenotypes linked to disease behaviour of our patient's fibrotic lung disease.
Other: Quality of life questionnaires.
Qality of life questionnaires including; modified Medical Research Council (mMRC) dyspnea scale, The King's Brief Interstitial Lung Disease Questionnaire (KBILD), The Leister Cough Questionnaire and the EQ-5D-3L questionnaire are measured at 0, 6 and 12 months
Diagnostic test: Genetic Testing
10ml of serum will be collected for DNA extraction and analysed for causative and at risk genetic mutations
Diagnostic test: Spirometry
We will carry out spirometry at baseline, 6 and 2 months including forced vital capacity and diffusing capacity of the lungs for carbon monoxide.
Diagnostic test: Serology
Serology which may indicate an underlying diagnosis of ILD will be carried out on study entry. This will include a full blood count, renal profile, liver profile, C-reactive protein, creatine kinase, erythrocyte sedimentation rate, antinuclear antibodies, anticyclic citrullinated peptide antibodies, rheumatoid factor, an extended myositis antibody panel, sjögren's antibodies, scleroderma antibodies and a hypersensivity pneumonitis panel if clinically indicated.
Other: PatientMPower Home Monitoring App
Continuous at home monitoring of patients using home-based digital spirometry and pulse-oximetry with real-time feedback readings to patient and clinician. Smartphone app for patients, spirometer and pulse oximeter are connected to the app via Bluetooth. Patients are asked to take 2 readings per week.
Idiopathic pulmonary fibrosis group
Patients meeting the study inclusion criteria with an MDT diagnosis of IPF in accordance with consensus criteria, ATS, ERS, JRS, ALAT guidelines, without a family history of pulmonary fibrosis.
Diagnostic test: Six minute walk test (6MWT)
Assessment of exercise capacity by the carrying out of a 6MWT at 0, 6 and 12 months.
Diagnostic test: Computer-tomography of the thorax (CT Thorax)
Radiological assessment via CT Thorax, preferably high-resolution CT thorax at baseline on entering the study and at one year. CT images will be collected on study end. CT images in all subjects will be evaluated by three readers blinded to any other interpretation and conforming to ATS-guidelines. Coded data from CT scans will be shared with our collaborator Professor Simon Walsh at Imperial College, London who will use computational methods to identify novel radiologic phenotypes linked to disease behaviour of our patient's fibrotic lung disease.
Other: Quality of life questionnaires.
Qality of life questionnaires including; modified Medical Research Council (mMRC) dyspnea scale, The King's Brief Interstitial Lung Disease Questionnaire (KBILD), The Leister Cough Questionnaire and the EQ-5D-3L questionnaire are measured at 0, 6 and 12 months
Diagnostic test: Genetic Testing
10ml of serum will be collected for DNA extraction and analysed for causative and at risk genetic mutations
Diagnostic test: Spirometry
We will carry out spirometry at baseline, 6 and 2 months including forced vital capacity and diffusing capacity of the lungs for carbon monoxide.
Diagnostic test: Serology
Serology which may indicate an underlying diagnosis of ILD will be carried out on study entry. This will include a full blood count, renal profile, liver profile, C-reactive protein, creatine kinase, erythrocyte sedimentation rate, antinuclear antibodies, anticyclic citrullinated peptide antibodies, rheumatoid factor, an extended myositis antibody panel, sjögren's antibodies, scleroderma antibodies and a hypersensivity pneumonitis panel if clinically indicated.
Other: PatientMPower Home Monitoring App
Continuous at home monitoring of patients using home-based digital spirometry and pulse-oximetry with real-time feedback readings to patient and clinician. Smartphone app for patients, spirometer and pulse oximeter are connected to the app via Bluetooth. Patients are asked to take 2 readings per week.
Connective tissue disease related interstitial lung disease group
Patients meeting the study inclusion criteria who meet the American College of Rheumatology/European League Against Rheumatism criteria for rheumatoid arthritis, scleroderma, Sjogren's syndrome, idiopathic inflammatory myopathy and systemic lupus erythematosus criteria
Diagnostic test: Six minute walk test (6MWT)
Assessment of exercise capacity by the carrying out of a 6MWT at 0, 6 and 12 months.
Diagnostic test: Computer-tomography of the thorax (CT Thorax)
Radiological assessment via CT Thorax, preferably high-resolution CT thorax at baseline on entering the study and at one year. CT images will be collected on study end. CT images in all subjects will be evaluated by three readers blinded to any other interpretation and conforming to ATS-guidelines. Coded data from CT scans will be shared with our collaborator Professor Simon Walsh at Imperial College, London who will use computational methods to identify novel radiologic phenotypes linked to disease behaviour of our patient's fibrotic lung disease.
Other: Quality of life questionnaires.
Qality of life questionnaires including; modified Medical Research Council (mMRC) dyspnea scale, The King's Brief Interstitial Lung Disease Questionnaire (KBILD), The Leister Cough Questionnaire and the EQ-5D-3L questionnaire are measured at 0, 6 and 12 months
Diagnostic test: Genetic Testing
10ml of serum will be collected for DNA extraction and analysed for causative and at risk genetic mutations
Diagnostic test: Spirometry
We will carry out spirometry at baseline, 6 and 2 months including forced vital capacity and diffusing capacity of the lungs for carbon monoxide.
Diagnostic test: Serology
Serology which may indicate an underlying diagnosis of ILD will be carried out on study entry. This will include a full blood count, renal profile, liver profile, C-reactive protein, creatine kinase, erythrocyte sedimentation rate, antinuclear antibodies, anticyclic citrullinated peptide antibodies, rheumatoid factor, an extended myositis antibody panel, sjögren's antibodies, scleroderma antibodies and a hypersensivity pneumonitis panel if clinically indicated.
Other: PatientMPower Home Monitoring App
Continuous at home monitoring of patients using home-based digital spirometry and pulse-oximetry with real-time feedback readings to patient and clinician. Smartphone app for patients, spirometer and pulse oximeter are connected to the app via Bluetooth. Patients are asked to take 2 readings per week.
Other: Other Quality of Life Questionnaires
Patient Global Assessment and Clinician Global Assessment scores completed at 0, 6 and 12 months

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Determine if familial-pulmonary-fibrosis is more progressive than sporadic-IPF
Time Frame: 12-months of entering the study
Disease progression defined as relative FVC decline ≥10% or death/lung transplant within 12 months of entering the study.
12-months of entering the study

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
All-cause mortality
Time Frame: Time of censoring or 12 months
Time of censoring or 12 months
Identify genotypes present in our study population
Time Frame: Within first 6 months of study recruitment
Identify pathogenic genetic variants known to cause ILD present in our study population as well as at risk alleles e.g. MUC5B.
Within first 6 months of study recruitment
Change in quality of life scores from baseline to 1 year
Time Frame: From date of study entry (baseline) until 12-month-assessment questionnaire completed, 12 months
Identify the number of participants with a change in their quality of life (QOL) scores over a twelve month period and if the change in QOL score is more likely to be associated factors such as genotype. Quality of life will be assessed based on the results of quality of life questionnaires completed including the Medical Research Council Dyspnoea Scale, Leicester Cough Questionnaire, The King's Brief Interstitial Lung Disease and EQ-5D-5L. The CTD-ILD cohort will also have Patient Global Assessment and Clinician Global Assessment scores recorded. These will be completed as close as possible to 0 months for the baseline score and at 6 and 12 months to assess for a change.
From date of study entry (baseline) until 12-month-assessment questionnaire completed, 12 months
Change in 6MWT from baseline to 1 year
Time Frame: On entry to study (baseline) to end of observation period (12 months)
6-Minute walk tests will be carried out in a clinical setting by a trained physiotherapist at baseline (0), 6 and 12 months.
On entry to study (baseline) to end of observation period (12 months)
Change in pulmonary function tests from baseline to 1 year
Time Frame: Baseline (0 months) to 12 month follow-up
Changes in forced vital capacity and diffusing capacity of the lungs for carbon monoxide will be assessed
Baseline (0 months) to 12 month follow-up
Changes and patterns in at home-spirometry with the patientMpower App
Time Frame: 12 Months
Using the patientMpower App patients will take twice-weekly home spirometry readings which will be analysed for changes and patterns in spirometry readings
12 Months
Change in HRCT scan
Time Frame: 12 months
Comparison between baseline CT Thorax and follow-up CT scan 1 year later using American Thoracic Society Guidelines to determine if there is radiological progression.
12 months
Identify radiological phenotypes linked to disease behavior in pulmonary fibrosis
Time Frame: 12 months
Use of computational methods to identify novel radiologic phenotypes linked to disease behaviour
12 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Royal College of Surgeons, Ireland

Collaborators

Imperial College London
patientMpower Ltd.

Investigators

  • Principal Investigator: Killian Hurley, RCSI

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 28, 2021

Primary Completion (Estimated)

July 1, 2026

Study Completion (Estimated)

April 1, 2028

Study Registration Dates

First Submitted

June 6, 2024

First Submitted That Met QC Criteria

November 20, 2024

First Posted (Estimated)

November 22, 2024

Study Record Updates

Last Update Posted (Estimated)

November 22, 2024

Last Update Submitted That Met QC Criteria

November 20, 2024

Last Verified

June 1, 2024

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • PRECISE-PF

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Connective Tissue Diseases

Clinical Trials on Six minute walk test (6MWT)

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Djibouti

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe